• Organizations: Adverum Biotechnologies
Adverum reports extended 4-year findings on wet AMD gene therapy
Pipeline

Adverum reports extended 4-year findings on wet AMD gene therapy

Promising results from the OPTIC extension program support long-term benefits of Ixo-vec in reducing treatment burden of anti-VEGF injections.
Adverum releases positive phase 2 data on wet AMD gene therapy
Pipeline

Adverum releases positive phase 2 data on wet AMD gene therapy

Investigators of the LUNA study select promising dosage of Ixo-vec determined to have a predictable long-term favorable safety profile for a planned phase 3 program.
Adverum receives FDA RMAT designation for wet AMD gene therapy
Pipeline

Adverum receives FDA RMAT designation for wet AMD gene therapy

Ixoberogene-soroparvovec is being clinically evaluated as a durable, well-tolerated, and cost-effective, in-office treatment option with extended efficacy following a single injection.
Adverum Biotech reports positive data from phase 2 LUNA study for wet AMD
Pipeline

Adverum Biotech reports positive data from phase 2 LUNA study for wet AMD

Vectorized therapeutic protein of aflibercept demonstrated annualized reduction in anti-VEGF injection rates of 90%.
Adverum Biotechnologies raises $127.5 million for gene therapy pipeline
Pipeline

Adverum Biotechnologies raises $127.5 million for gene therapy pipeline

Private placement financing funds Ixo-vec clinical development program through 2025.